The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Open accessAbstract
BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC. METHODS: In this double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]-paclitaxel for the first 4 cycles. Primary end points were overall survival and progression-free survival. RESULTS: After a median follow-up of 7.8 months, the median overall survival was 15.9 months (95% confidence interval [CI], 13.2 to not reached) in the pembrolizumab-combination group and 11.3 months (95% CI, 9.5 to 14.8) in the placebo-combination group (hazard ratio for death, 0.64; 95% CI, 0.49 to 0.85; P<0.001). The overall survival benefit was consistent regardless of the level of PD-L1 expression. The median progression-free survival was 6.4 months (95% CI, 6.2 to 8.3) in the pembrolizumab-combination group and 4.8 months (95% CI, 4.3 to 5.7) in the placebo-combination group (hazard ratio for disease progression or death, 0.56; 95% CI, 0.45 to 0.70; P<0.001). Adverse events of grade 3 or higher occurred in 69.8% of the patients in the pembrolizumab-combination group and in 68.2% of the patients in the placebo-combination group. Discontinuation of treatment because of adverse events was more frequent in the pembrolizumab-combination group than in the placebo-combination group (13.3% vs. 6.4%). CONCLUSIONS: In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck Sharp & Dohme; KEYNOTE-407 ClinicalTrials.gov number, NCT02775435 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“chemotherapy plus immune checkpoint blockade has been recently approved as the first-line regimen for NSCLC, including patients with KRAS mutations (45, 46).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [45]
In the citing paper
“Importantly, two remarkable phase III trials (KEYNOTE-189 and KEYNOTE-407) demonstrated that addition of pembrolizumab (Keytruda, anti-PD1) could significantly prolong the survival of NSCLC patients (45, 97).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [45]
In the citing paper
“The promising results from these studies have led to the approval of pembrolizumab in combination with chemotherapy (carboplatin-pemetrexed) for metastatic, non-squamous NSCLC, and the approval of pembrolizumab in combination with chemotherapy (carboplatin and Taxol) for patients with squamous lung carcinoma, excluding those carrying EGFR or ALK mutations.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [45]
In the citing paper
“Toward this end, combinations of ICTs with concurrent and/or sequential chemotherapy are under extensive investigation, with phase III clinical data demonstrating overall survival and/or progression-free survival benefi t in NSCLC ( 63-66 ), small cell lung cancer ( 51,52 ), triple-negative breast cancer ( 67 ), bladder cancer ( 53 ), and head and neck squamous cell carcinoma ( 68 ).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [64]
In the citing paper
“Later, in two phase 3 clinical studies (KEYNOTE-189 and KEYNOTE-407), pembrolizumab combined with standard chemotherapy led to a better overall survival (OS) and PFS in NSCLC patients, relative to chemotherapy monotherapy [53, 54].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [54]
In the citing paper
“Moreover, ORR, median PFS, and median DOR reported for the two treatment arms were consistent with those reported in the KEYNOTE-189 and KEYNOTE-407 trials of pembrolizumab i.v.þ chemotherapy for the treatment of mNSCLC.22,23”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationRittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Self-citationNivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
Self-citationFirst-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,006
Cortellini, A., Cannita, K., Tiseo, M., Cortinovis, D. L., Aerts, J. G. J. V., Baldessari, C., Giusti, R., Ferrara, M. G., D’Argento, E., Grossi, F., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.005 · Cited by 33
Zhou, C., Wang, J., Wang, B., Cheng, Y., Wang, Z., Han, B., Lü, Y., Wu, G., Zhang, L., Song, Y., et al. (2021) · PubMed Central · doi:10.3779/j.issn.1009-3419.2021.101.13 · Cited by 32
Self-citationBrueckl, W. M., Reck, M., Rittmeyer, A., Kollmeier, J., Wesseler, C., Wiest, G. H., Christopoulos, P., Stenzinger, A., Tufman, A., Hoffknecht, P., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-197 · Cited by 32
Shiraishi, Y., Hakozaki, T., Nomura, S., Kataoka, T., Tanaka, K., Miura, S., Sekino, Y., Ando, M., Horinouchi, H., Ohe, Y., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.10.012 · Cited by 32
Wang, X., Cang, W., Liu, X., Cheng, Y., Wan, X., Feng, F., Ren, T., Zhao, J., Jiang, F., Cheng, H., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101974 · Cited by 32
Self-citationKawachi, H., Yamada, T., Tamiya, M., Negi, Y., Gotô, Y., Nakao, A., Shiotsu, S., Tanimura, K., Takeda, T., Okada, A., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.22915 · Cited by 33
Cruz, M. C. P. D., & Medina, P. M. B. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.07.001 · Cited by 34
Costantini, A., Kamga, P. T., Duménil, C., Chinet, T., Emile, J., & Leprieur, E. G. (2019) · Cancers · doi:10.3390/cancers11091269 · Cited by 32
Durvalumab for the treatment of non-small cell lung cancer
Murakami, S. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1699407 · Cited by 33
Principles of Immunotherapy in Non-Small Cell Lung Cancer
Hsu, M. L., & Naidoo, J. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.009 · Cited by 33
Brueckl, W. M., Reck, M., Rittmeyer, A., Kollmeier, J., Wesseler, C., Wiest, G. H., Christopoulos, P., Tufman, A., Hoffknecht, P., Ulm, B., et al. (2020) · Clinical Medicine Insights Oncology · doi:10.1177/1179554920951358 · Cited by 33
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer
Duchemann, B., Remón, J., Naigeon, M., Cassard, L., Jouniaux, J.-M., Boselli, L., Grivel, J., Auclin, É., Desnoyer, A., Besse, B., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-839 · Cited by 33
Management of chemotherapy-induced alopecia (CIA): A comprehensive review and future directions
Haque, E., Alabdaljabar, M. S., Ruddy, K. J., Haddad, T. C., Thompson, C. A., Lehman, J. S., & Hashmi, S. K. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103093 · Cited by 32
Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma
Zhao, Y., Shi, F., Zhou, Q., Li, Y., Wu, J., Wang, R., & Song, Q. (2020) · Medicine · doi:10.1097/md.0000000000023172 · Cited by 35
Comprehensive Genomic Profiling for Non-Small-Cell Lung Cancer: Health and Budget Impact
Johnston, K., Sheffield, B. S., Yip, S. S. F., Lakzadeh, P., Qian, C. J., & Nam, J. (2020) · Current Oncology · doi:10.3747/co.27.5995 · Cited by 32
Furuya, N., Nishino, M., Wakuda, K., Ikeda, S., Sato, T., Ushio, R., Tanzawa, S., Sata, M., & Ito, K. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13824 · Cited by 32
Hypoxia in Lung Cancer Management: A Translational Approach
Ancel, J., Perotin, J., Dewolf, M., Launois, C., Mulette, P., Nawrocki‐Raby, B., Dalstein, V., Gilles, C., Deslée, G., Polette, M., et al. (2021) · Cancers · doi:10.3390/cancers13143421 · Cited by 32
Butter, R., Hondelink, L. M., van Elswijk, L., Blaauwgeers, J. L. G., Bloemena, E., Britstra, R., Bulkmans, N. W. J., van Gulik, A. L., Monkhorst, K., de Rooij, M. J., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.03.002 · Cited by 33
Jung, H. A., Park, K. U., Cho, S., Lim, J., Lee, K., Hong, M. H., Yun, T., An, H. J., Park, W., Pereira, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1238 · Cited by 32
Self-citationThe Profile and Clinical Significance of ITGB2 Expression in Non-Small-Cell Lung Cancer
Zu, L., He, J., Zhou, N., Zeng, J., Zhu, Y., Tang, Q., Jin, X., Zhang, L., & Xu, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216421 · Cited by 33
Waissengrin, B., Leshem, Y., Taya, M., Meiri, D., Merimsky, O., Shamai, S., Wolf, I., & Rubinek, T. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.11.022 · Cited by 32
Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
Russano, M., Cava, G. L., Cortellini, A., Citarella, F., Galletti, A., Fazio, G. R. D., Santo, V., Brunetti, L., Vendittelli, A., Fioroni, I., et al. (2023) · Current Oncology · doi:10.3390/curroncol30020181 · Cited by 34
Dougan, M. L. (2020) · Current Gastroenterology Reports · doi:10.1007/s11894-020-0752-z · Cited by 33
Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells
Okimoto, T., Kotani, H., Iida, Y., Koyanagi, A., Tanino, R., Tsubata, Y., Isobe, T., & Harada, M. (2020) · Cancer Science · doi:10.1111/cas.14401 · Cited by 31
Auclin, É., Benítez, J. C., Tagliamento, M., Parisi, F., Gorría, T., García‐Campelo, R., Dempsey, N. G., Pinato, D. J., Reyes, R., Albarrán-Artahona, V., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.02.002 · Cited by 31
Ohashi, K., Nishito, Y., Fukuda, H., Sadahiro, R., Yoshida, Y., WATANABE, S.-I. I., Motoi, N., Sonobe, Y., Mizuno, H., Tsunoda, H., et al. (2024) · Scientific Reports · doi:10.1038/s41598-023-50378-9 · Cited by 33
Hertz, D. L., Joerger, M., Bang, Y., Mathijssen, R. H. J., Zhou, C., Zhang, L., Gandara, D. R., Stahl, M., Monk, B. J., Jaehde, U., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114024 · Cited by 31
The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer
Hermel, D. J., & Sigal, D. S. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9010005 · Cited by 31
Liang, H., Liu, Z., Cai, X., Pan, Z., Chen, D., Li, C., Chen, Y., He, J., & Liang, W. (2019) · International Journal of Cancer · doi:10.1002/ijc.32366 · Cited by 31
Reimers, M. A., Slane, K., & Pachynski, R. K. (2019) · Current Urology Reports · doi:10.1007/s11934-019-0931-3 · Cited by 30
Hoffner, B., Leighl, N. B., & Davies, M. J. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101979 · Cited by 30
Chan, G. H. J., Gwee, Y. X., Low, J. L., Huang, Y., Chan, Z. Y., Choo, J. R. E., Ngoi, N. Y. L., Ang, Y. L. E., Muthu, V., Chong, W. Q., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.05.020 · Cited by 31
Porter, L., & McCaughan, F. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.007 · Cited by 30
Jiang, H., Zheng, Y., Qian, J., Mao, C., Xu, X., Li, N., Cheng, X., Wang, H., Teng, L., Zhou, H., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02738-x · Cited by 31
Mountzios, G., Toma, A. D., Economopoulou, P., Friedlaender, A., Banini, M., Russo, G. L., Baxevanos, P., Roila, F., Banna, G. L., Christopoulou, A. N., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.09.017 · Cited by 31
Pathak, R., Lopes, G. D. L., Jr., Yu, H., Aryal, M. R., Ji, W., Frumento, K. S., Wallis, C. J. D., Klaassen, Z. W. A., Park, H. S.-M., & Goldberg, S. B. (2020) · Cancer · doi:10.1002/cncr.33269 · Cited by 30
Chen, X., Yuan, S., Duan, J., Chen, Y.-M., Chen, S., Wang, Y., & Li, Y. (2020) · Disease Markers · doi:10.1155/2020/6717912 · Cited by 32
Xu, Y., Li, H., Huang, Z., Chen, K., Yu, X., Sheng, J., Zhang, H., & Fan, Y. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1130 · Cited by 31
Goggi, J., Hartimath, S. V., Xuan, T. Y., Khanapur, S., Jieu, B., Chin, H. X., Ramasamy, B., Cheng, P. K. C., Rong, T. J., Yong, F., et al. (2021) · Molecular Imaging and Biology · doi:10.1007/s11307-021-01596-y · Cited by 31
Yao, W., Zhao, X., Gong, Y., Zhang, M., Zhang, L., Wu, Q., Wu, L., Fan, Z., Yan, X., & Jiao, S. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100094 · Cited by 32
Li, H., Qin, S., Liu, Y., Chen, Z., Ren, Z., Xiong, J., Meng, Z., Zhang, X., Wang, L., Zhang, X., et al. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s304857 · Cited by 32
Xiong, Q., Qin, B., Xin, L., Yang, B. Y., Song, Q., Wang, Y., Zhang, S., & Hu, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659380 · Cited by 33
Doroshow, D. B., Wei, W., Gupta, S., Zugazagoitia, J., Robbins, C. T., Adamson, B. J. S., & Rimm, D. L. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.032 · Cited by 31
Takada, K., Takamori, S., Shimokawa, M., Toyokawa, G., Shimamatsu, S., Hirai, F., Tagawa, T., Okamoto, T., Hamatake, M., Tsuchiya‐Kawano, Y., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100348 · Cited by 31
Xu, X., Wang, D., Chen, W., Li, N., Suwiński, R., Rossi, A., Rosell, R., Zhong, J., & Fan, Y. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-899 · Cited by 30
Bird, B., Nally, K., Ronan, K. E., Clarke, G. A., Amu, S., Almeida, A. S., Flavin, R., & Finn, S. P. (2022) · Diagnostics · doi:10.3390/diagnostics12010124 · Cited by 29
Lehrer, E. J., Gurewitz, J., Bernstein, K., Patel, D., Kondziolka, D. S., Niranjan, A., Wei, Z., Lunsford, L. D., Malouff, T. D., Ruiz-Garcia, H. J., et al. (2022) · Cancer · doi:10.1002/cncr.34087 · Cited by 31
Olivares-Hernández, A., del Barco, E., Pérez, C. P., Miramontes‐González, J. P., Figuero-Pérez, L., Gómez, T. M., Cornejo, R. A. E., Hernández, L. B., González‐Sarmiento, R., Cruz, J. J., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020360 · Cited by 30
Effects of Concomitant Antibiotics Use on Immune Checkpoint Inhibitor Efficacy in Cancer Patients
Jiang, S., Geng, S., Chen, Q., Zhang, C., Cheng, M., Yu, Y., Zhang, S., Shi, N., & Dong, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.823705 · Cited by 31
Imaging immunity in patients with cancer using positron emission tomography
Hegi‐Johnson, F., Rudd, S. E., Hicks, R. J., Ruysscher, D. D., Trapani, J. A., John, T., Donnelly, P. S., Blyth, B. J., Hanna, G. G., Everitt, S., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00263-x · Cited by 33
Rebuzzi, S. E., Prelaj, A., Friedlaender, A., Cortellini, A., Addeo, A., Genova, C., Naqash, A. R., Auclin, É., Mezquita, L., & Banna, G. L. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103806 · Cited by 34
Yan, W., Zhong, W., Liu, Y., Chen, Q., Xing, W., Zhang, Q., Liu, L., Ge, D., Chen, K., Yang, F., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.09.222 · Cited by 33
Bronte, G., Calabrò, L., Olivieri, F., Procopio, A. D., & Crinò, L. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00946-6 · Cited by 31
Sathiyapalan, A., Febbraro, M., Pond, G. R., & Ellis, P. M. (2022) · Current Oncology · doi:10.3390/curroncol29120709 · Cited by 31
How to Manage a Patient with Ocular Metastases?
Thariat, J., Boudin, L., Loria, O., Nguyen, A.-M., Kodjikian, L., & Mathis, T. (2022) · Biomedicines · doi:10.3390/biomedicines10123044 · Cited by 31
O'Byrne, K. J., Popoff, E., Badin, F. B., Lee, A., Yuan, Y., Lozano‐Ortega, G., Eccles, L. J., Varol, N., Waser, N. A., Penrod, J. R., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.01.006 · Cited by 31
Reck, M., Popat, S., Grohé, C., Corral, J., Novello, S., Gottfried, M., Brueckl, W. M., Radonjic, D., Kaiser, R., & Heymach, J. V. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.03.009 · Cited by 32
Self-citationShaikh, F. Y., Gills, J. J., Mohammad, F., White, J. R., Stevens, C. M., Ding, H., Fu, J., Tam, A., Blosser, R. L., Domingue, J. C., et al. (2022) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-022-03169-6 · Cited by 30
Belaroussi, Y., Bouteiller, F., Bellera, C. A., Pasquier, D., Pérol, M., Debieuvre, D., Filleron, T., Girard, N., Schött, R., Mathoulin‐Pélissier, S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-36623-1 · Cited by 30
Li, R., Liang, H., Li, J., Shao, Z., Yang, D., Bao, J., Wang, K., Wen, X., Gao, Z., Guo, R., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-11860-3 · Cited by 31
Sorbini, M., Carradori, T., Togliatto, G., Vaisitti, T., & Deaglio, S. (2024) · Biomolecules · doi:10.3390/biom14040498 · Cited by 32
Cortellini, A., Brunetti, L., Fazio, G. R. D., Garbo, E., Pinato, D. J., Naidoo, J., Katz, A., Loza, M., Neal, J. W., Genova, C., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010674 · Cited by 33
Song, J., Zhu, J. W., Jiang, Y., Guo, Y., Liu, S., Qiao, Y., Du, Y., & Li, J. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189277 · Cited by 31
Zhang, L., Sun, L., Yu, J., Shan, F., Zhang, K., Pang, X., Ma, C., Zhang, Y., Shen, M., Ma, S., et al. (2019) · BioMed Research International · doi:10.1155/2019/9853701 · Cited by 30
Yoshimura, A., Yamada, T., Okuma, Y., Kitadai, R., Takeda, T., Kanematsu, T., Goto, H., Yoneda, H., Harada, T., Kubota, Y., et al. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.08.07 · Cited by 30
Robertson, J. D., Salm, M., & Dangl, M. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.09.003 · Cited by 31
Chen, Y., Zhou, Y., Tang, L., Peng, X., Jiang, H. F., Guo, W., & Zhuang, W. (2019) · Journal of Cancer · doi:10.7150/jca.34677 · Cited by 30
Smit, H. J. M., Aerts, J. G. J. V., van den Heuvel, M. M., Hiltermann, T. J. N., Bahce, I., Smit, E. F., Dingemans, A. C., Hendriks, L. E. L., Stigt, J. A., Schramel, F. M. N. H., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.12.011 · Cited by 30
Iivanainen, S., & Koivunen, J. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020556 · Cited by 30
Cantini, L., Merloni, F., Rinaldi, S., Lenci, E., Marcantognini, G., Meletani, T., Fiordoliva, I., Morgese, F., Torniai, M., Ricci, G., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102974 · Cited by 31
Han, J., Tian, K., Yang, J., & Gong, Y. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.05.011 · Cited by 30
Saxena, P., Singh, P. K., Malik, P. S., & Singh, N. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00768-2 · Cited by 30
Satouchi, M., Nosaki, K., Takahashi, T., Nakagawa, K., Aoe, K., Kurata, T., Sekine, A., Horiike, A., Fukuhara, T., Sugawara, S., et al. (2020) · Cancer Science · doi:10.1111/cas.14647 · Cited by 30
Self-citationRetractedReview of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date
Tacconi, E. M., Tuthill, M. H., & Protheroe, A. S. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s174149 · Cited by 30
The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma
Yuan, H., Liu, J., & Zhang, J. (2021) · Molecules · doi:10.3390/molecules26051392 · Cited by 30
Nie, R., Chen, G.-M., Wang, Y., Zhou, J., Duan, J., Zhou, Z., & Yuan, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.538174 · Cited by 31
Kong, X., Lü, P., Liu, C., Guo, Y., Yang, Y., Peng, Y., Wang, F., Zhang, B., Dou, X., Shi, H., et al. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12001 · Cited by 30
Huang, Y., Soon, Y. Y., Aminkeng, F., Tay, S. H., Ang, Y. L. E., Kee, A. C.-L., Goh, B. C., Wong, A. S. C., & Soo, R. A. (2021) · International Journal of Cancer · doi:10.1002/ijc.33822 · Cited by 30
Chen, Y., Jia, M., Wang, S., Xu, S., & He, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835690 · Cited by 32
Barth, D. A., Stanzer, S., Terzic, J. A., Bauernhofer, T., Absenger, G., Posch, F., Lipp, R., Halm, M., Szkandera, J., Balić, M., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4675 · Cited by 29
Somasundaram, A., Cillo, A. R., Lampenfeld, C., Workman, C. J., Kunning, S. R., Oliveri, L., Velez, M. A., Joyce, S. C., Calderon, M. J., Dadey, R., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0736 · Cited by 30
Pulmonary adverse events following immune checkpoint inhibitors
Spagnolo, P., Chaudhuri, N., Bernardinello, N., Karampitsakos, Τ., Sampsonas, F., & Tzouvelekis, A. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000895 · Cited by 31
Guezour, N., Soussi, G., Brosseau, S., Abbar, B., Naltet, C., Vauchier, C., Poté, N., Hachon, L., Namour, C., Khalil, A., et al. (2022) · Cancers · doi:10.3390/cancers14163878 · Cited by 30
Paz-Ares, L. G., Ciuleanu, T., Płużański, A., Lee, J., Gainor, J. F., Otterson, G. A., Audigier-Valette, C., Ready, N., Schenker, M., Linardou, H., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.08.014 · Cited by 31
Self-citationGao, L., Jiang, W., Yue, Q., Ye, R., Li, Y., Hong, J., & Zhang, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109335 · Cited by 30
Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC
Goh, K. Y., Cheng, T. Y. D., Tham, S. C., & Lim, W. (2023) · Biomedicines · doi:10.3390/biomedicines11020508 · Cited by 31
Losmanová, T., Janser, F. A., Humbert, M., Tokarchuk, I., Schläfli, A. M., Neppl, C., Schmid, R. A., Tschan, M. P., Langer, R., & Berezowska, S. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/8506572 · Cited by 30
Rangachari, D., & Costa, D. B. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01207 · Cited by 31
Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
Catalano, M., Shabani, S., Venturini, J., Ottanelli, C., Voltolini, L., & Roviello, G. (2022) · Cancers · doi:10.3390/cancers14246145 · Cited by 29
MTAP as an emerging biomarker in thoracic malignancies
Brune, M. M., Prince, S. S., Vlajnic, T., Chijioke, O., Roma, L., König, D., & Bubendorf, L. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107963 · Cited by 38
Soda, H., Ogawara, D., Fukuda, Y., Tomono, H., Okuno, D., Koga, S., Taniguchi, H., Yoshida, M., Harada, T., Umemura, A., et al. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12952 · Cited by 29
Edahiro, R., Kanazu, M., Kurebe, H., Mori, M., Fujimoto, D., Taniguchi, Y., Suzuki, H., Hirano, K., Yokoyama, T., Morita, M., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220570 · Cited by 29
Hanna, N. H., Temin, S., & Masters, G. A. (2020) · JCO Oncology Practice · doi:10.1200/jop.19.00770 · Cited by 30
Fu, D., Wu, J., Lai, J., Liu, Y., Zhou, L., Chen, L., & Zhang, Q. (2020) · PubMed Central · Cited by 29
Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial
Remón, J., Besse, B., Leary, A. F., Bièche, I., Job, B., Lacroix, L., Auguste, A., Mauduit, M., Audigier-Valette, C., Raimbourg, J., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100068 · Cited by 28
Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer
Adderley, H., Blackhall, F. H., & Lindsay, C. R. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02714-5 · Cited by 29
Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer
Gavralidis, A., & Gainor, J. F. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000491 · Cited by 28
Arita, M., Watanabe, S., Aoki, N., Kuwahara, S., Suzuki, R., Goto, S., Abe, Y., Takahashi, M., Sato, M., Hokari, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-80853-6 · Cited by 29
CLEVERS, M. R., Kastelijn, E. A., Peters, B. J. M., Kelder, H. C., & Schramel, F. M. N. H. (2021) · Anticancer Research · doi:10.21873/anticanres.14839 · Cited by 29
Zheng, M.-M., Tu, H., Yang, J., Zhang, X., Zhou, Q. H., Xu, C., Jiang, B., Yang, X., Yang, X., Deng, J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.037 · Cited by 29
Metadata
- Authors
- Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., Rodríguez-Cid, J., Wilson, J., Sugawara, S., Kato, T., Lee, K. H., Cheng, Y., Novello, S., Halmos, B., Li, X., Lubiniecki, G. M., Piperdi, B., & Kowalski, D. M.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- From Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center, Universidad Complutense and Ciberonc, Madrid (L.P.-A.), and Hospital Universitario Virgen Macarena, Seville (D.V.) — both in Spain; Leningrad Regional Clinical Hospital, St. Petersburg, Russia (A.L.); Wollongong Oncology and Wollongong Private Hospital, Wollongong, NSW, Australia (A.T.); Istanbul Medeniyet University Hospital, Istanbul (M.G.), and Ankara University, Ankara (F.Ç.Ş.) — both in Turkey; Centre...
- Ankara University (TR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-22
- Volume
- 379
- Issue
- 21
- Pages
- 2040-2051
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2892640821
- Cited by
- 3,617
- References
- 26
- Citations by year
- 2026: 220 · 2025: 328 · 2024: 445 · 2023: 440 · 2022: 565 · 2021: 630 · 2020: 606 · 2019: 361 · 2018: 16
- FWCI
- 303.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- Merck (N/A)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- pembrolizumab, lung squamous cell carcinoma, metastatic lung cancer, PD-L1 expression, immune checkpoint inhibitors, carboplatin, paclitaxel, nab-paclitaxel, first-line therapy, overall survival, progression-free survival, immune-related adverse events, treatment discontinuation, chemoimmunotherapy, PD-1 inhibitors
- MeSH terms
- Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Analysis, Carboplatin, Paclitaxel, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
